JPS61129117A - Aloe-containing cataplasm - Google Patents
Aloe-containing cataplasmInfo
- Publication number
- JPS61129117A JPS61129117A JP59249702A JP24970284A JPS61129117A JP S61129117 A JPS61129117 A JP S61129117A JP 59249702 A JP59249702 A JP 59249702A JP 24970284 A JP24970284 A JP 24970284A JP S61129117 A JPS61129117 A JP S61129117A
- Authority
- JP
- Japan
- Prior art keywords
- aloe
- skin
- cataplasm
- plaster
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、薬学的に優れた新規なアロエ含有のパップ剤
に関し、更に詳しくは、パップ剤の剤型にアロエ末また
はアロエ液を配合してなる強力な抗炎症作用を有するパ
ップ剤に関するものである(従来の技術)
周知のよ5に、アロエは新鮮な葉からしぼった液が薬用
とされ、そのアロエ液を火熱乾固したものは0.21前
後の服用により、苦味強壮、健胃、緩下剤として内用に
用いられている。一方、民間では、新鮮なアロエ液は応
急外用系として使用されており、火傷、ひび、あかぎれ
、ニキビ、小さな切傷、日焼け、抜毛(脱毛)などに題
亜または湿布して用いられ、止血、炎症緩和、痛み止、
化1糺防止、局所肉芽組織再生促進などに効果があるこ
とが知られている。Detailed Description of the Invention (Industrial Field of Application) The present invention relates to a novel pharmaceutically excellent poultice containing aloe, and more specifically, to a poultice containing aloe powder or liquid. (Conventional technology) It is well known that the liquid squeezed from fresh aloe leaves is used medicinally, and that the aloe liquid is heated to dryness. It is used internally as a bitter tonic, stomachic, and laxative by taking a dose of around 0.21. On the other hand, in the private sector, fresh aloe vera liquid is used as an emergency topical system, and is used as a poultice or poultice for burns, cracks, chaps, acne, small cuts, sunburn, and hair removal (hair removal), to stop bleeding, and to prevent inflammation. Relief, pain relief,
It is known to be effective in preventing keratinosis and promoting local granulation tissue regeneration.
従来より生薬配合のパップ剤としてはオウバク末、サン
シシ末、セイヨウトチノミエキス、トウガラシエキスが
消炎鎮痛パック剤として用いられ、また、アロエ末はア
ロエ軟暫(アロエ展薬株式会社)として、ひび、しもや
け、あかぎれ、やけど、切傷、5%、打身に用いられて
いるが、末だアロエ末またはアロエ液を配合したパップ
剤は見当らない。Traditionally, poultices containing herbal medicines include Aurubaku powder, Sanshishi powder, Horsetail flea extract, and Capsicum extract, which have been used as anti-inflammatory and analgesic packs, and Aloe powder has been used as an anti-inflammatory and pain relief pack (Aloe Tenyaku Co., Ltd.) to treat cracks and chilblains. It is used for chaps, burns, cuts, and bruises, but no poultices containing aloe powder or aloe liquid have been found.
(発明が解決しようとする問題点)
ところで、従来用いられているアロエ汁およびアロエ未
配合軟貴製剤は
■ 使用時、アロエ汁あるいはアロエ軟鷺は肌や衣服を
汚染する
■ 一定号を均一な厚さに塗布できない■ 冬期におい
て軟(が固化し易く、基布は勿論のこと皮膚に対しても
展延性が悪(、充分に展延して値布しにくい
■ 使用終了後、アロエ汁やアロエ軟(が肌面に残留し
、拭き取る必要があり、簡便さに欠けるはかりでなく、
容易に拭き取ることができないなど、実用上において種
々の難点があり、前記効用には後れているものの、アロ
エの効用を充分に引き出す製剤ではないため、従来繁用
されるまでに至らなかったのが実情である。(Problems to be Solved by the Invention) By the way, the conventionally used aloe juice and soft preparations that do not contain aloe are: ■ When used, the aloe juice or aloe soft heron contaminates the skin and clothes. Cannot be applied thickly ■ Soft in winter (can harden easily and has poor spreadability not only on the base fabric but also on the skin) (spreads well and is difficult to price ■ After use, apply aloe juice or It is not a scale that is not convenient because aloe vera remains on the skin and needs to be wiped off.
It has various practical difficulties, such as not being easily wiped off, and although it lags behind the effects mentioned above, it is not a formulation that fully brings out the effects of aloe, so it has not been widely used in the past. is the reality.
(問題点を解決するための手段)
本発明者らは、アロエの外用面での研究を重ねた結果、
従来鎮痛、消炎の目的で使用されているパツプ剤の剤型
にアロエ末またはアロエ液を配合することにより前記ア
ロエ軟衛の有する不都合な点が除去されると共に、効果
が増強され特に強力な抗炎症作用を有することを見い出
して本発明を完成したものである。(Means for solving the problem) As a result of repeated research on the external use of aloe, the present inventors found that
By incorporating aloe powder or aloe liquid into the formulation of a poultice, which has been conventionally used for pain relief and anti-inflammatory purposes, the disadvantages of the aloe cream can be eliminated, and the effect can be enhanced, making it a particularly powerful anti-inflammatory agent. The present invention was completed by discovering that it has an inflammatory effect.
すなわち、本発明は、パップ剤の剤型にアロエ末または
アロエ液を配合した点に特徴があり、本発明において使
用し得るアロエ属植物は、ユリ科植物のアロエ属に属す
る諸種の植物のいずれをも使用することができるもので
あり、また、アロエ液はアロエ液汁とアロエエキスとを
包含するものである。That is, the present invention is characterized in that aloe powder or aloe liquid is blended into the dosage form of the poultice, and the plants of the genus Aloe that can be used in the present invention include any of various plants belonging to the genus Aloe of the Liliaceae family. Also, the aloe juice includes aloe juice and aloe extract.
本発明において、パップ剤はアロエ末または、アロエ液
、粉末状または水性ゲル基剤、保湿剤などから成り、添
加配合されるアロエ末またはアロエ液は電体全量に対し
て0.5Ji量%以上であることが好ましく、また、必
要により従来鎮痛、消炎を目的とするパップ剤の分野に
おいて汎用されているサリチル酸メチル、サリチル酸グ
リコールなどのサリチル酸エステル類カンフール、メン
トール、ハツカ類、ノニル酸ワニリルアミド、トウガラ
シエキス、ユウカリ油、ビタミンE1ビタミンのエステ
ル類、塩酸ジフェンヒドラミンなどの薬剤を添加するこ
とができる。In the present invention, the poultice consists of aloe powder or aloe liquid, a powdered or aqueous gel base, a moisturizing agent, etc., and the amount of aloe powder or aloe liquid added is 0.5 Ji amount% or more based on the total amount of the electric body. Salicylic acid esters such as methyl salicylate and glycol salicylate, camphor, menthol, peppers, nonylic acid vanillylamide, and capsicum extract, which are conventionally used in the field of poultices for the purpose of analgesia and anti-inflammatory treatment, are preferably used. , eucalyptus oil, vitamin E1 vitamin esters, diphenhydramine hydrochloride, and other agents can be added.
、パツプ剤の剤型としたことからアロエの効用が充分に
得られるばかりか、特に優れた抗炎症効果を有し、また
、本発明パップ剤は、その嘴体面や基布裏面からの有色
油状物のシ号出がなく、保水性、粘弾性、剥離性および
安定性に優れ、生薬成分の皮膚への浸透を高め、肌に対
して好ましい密着感があり、使用後肌面に1体が残留す
ることゝなく、かつ生薬成分、基剤成分が長期間変質す
ることがなく、更に従来基剤に比し効力が優れているも
のである。Since it is in the form of a poultice, not only can the efficacy of aloe be fully obtained, but it also has a particularly excellent anti-inflammatory effect. It does not cause any problems, has excellent water retention, viscoelasticity, peelability, and stability, increases the penetration of herbal medicine ingredients into the skin, has a good adhesion to the skin, and leaves no residue on the skin after use. There is no residue, the herbal medicine components and base components do not deteriorate over a long period of time, and the efficacy is superior to that of conventional bases.
(実施例)
以下、実施例および比較例を(げて説明するが、本発明
はこれによって限定されるものではない実施例
ポリアクリル酸ナトリウム 5.0
1酸化亜鉛 2.2fカルボキシ
メチルセルロースナトリウム 3.01グリセリン
30.(1ゼラチン
6.02クエン酸 4.
0?チモール 0.IPアロエ末
1.0?精製水 48
.71−
全量 100.Of
上記のポリアクリル酸ナトリウム、酸化亜鉛、カルボキ
シメチルセルロースナトリウム、チモールおよびアロエ
末を入れ充分に混合し、これにグリセリンを入れて練合
し、更にこれに予めゼラチンを精製水に53〜550C
で加温俗解させたゼラチン浴液およびクエン酸を入れ、
充分に檎拝線合して、アロエ末を含有するパップ剤を得
た。(Example) Examples and comparative examples will be described below, but the present invention is not limited thereto.Example Sodium polyacrylate 5.0
Zinc monoxide 2.2f Sodium carboxymethyl cellulose 3.01 Glycerin 30. (1 gelatin
6.02 Citric acid 4.
0? Thymol 0. IP aloe end 1.0? Purified water 48
.. 71- Total amount 100. Of the above-mentioned sodium polyacrylate, zinc oxide, sodium carboxymethyl cellulose, thymol and aloe powder were added and mixed thoroughly. Added glycerin and kneaded, and then added gelatin in purified water at 53-550C.
Add the heated gelatin bath solution and citric acid,
By thoroughly combining the ingredients, a poultice containing aloe powder was obtained.
本発明の前記実施例によって得られたアロエ末含有パツ
プ剤を用いて後述の方法によりラットによるカラゲニン
足J、浮埼に対する抑制作用と毛細血管透過性先進に対
する抑制作用を試験した。Using the aloe powder-containing poultices obtained in the above-mentioned embodiments of the present invention, the inhibitory effects on carrageenan foot J and floatation and the inhibitory effects on advanced capillary permeability in rats were tested by the method described below.
比較のため、アロエ末の代わりにセイヨクトチノミエキ
スおよびグアイアズレンを用いて実施例と同様に処理し
て比較例1および2の外用生薬パツプ剤を得、同様に試
験を行った。For comparison, topical herbal medicine patch preparations of Comparative Examples 1 and 2 were obtained by treating in the same manner as in the examples, except that the aloe vera powder was replaced with the extract and guaiazulene, and the tests were conducted in the same manner.
比較例1
セイヨウトチノミエキス(6:1) 0.5f
ポリアクリル酸ナトリウム 5.Of
酸化亜鉛 2.22カルボキシメ
チルセルロースナトリウム 3.Ofグリセリン
30.Orゼラチン
6.Ofクエン酸 4゜atチ
モール 0.1f比較例2
グアイアズレン 0.04fポリア
クリル酸ナトリウム 5.0?酸化亜
鉛 2.21カルボキシメチルセル
ロースナトリウム 3.Ofグリセリン
30.Or
ゼラチン 6.Ofクエン酸
4.Ofチモール
0.1f全量 100.0Of
試験例1
カラゲニン足び浮騎抑制試験
前記実施例および比較例1.2により得られたパップ剤
の3検体に無処理(起炎剤注射のみ)対照群等を加えた
6群で次の方法により試験を行ったO
飼育飼料とし【固形飼料RC−4(オリエンタル酵母社
製)を使用し、飼料、水ともに自由に摂取させたW i
s t a r系雄性ラット(体重122〜140?
、日本医科学動物資料研究所)を1群10匹として使用
した。Comparative Example 1 Horse chestnut flea extract (6:1) 0.5f
Sodium polyacrylate 5. Of
Zinc oxide 2.22 Sodium carboxymethyl cellulose 3. Of glycerin
30. Or gelatin
6. Of citric acid 4°at thymol 0.1f Comparative example 2 Guaiazulene 0.04f Sodium polyacrylate 5.0? Zinc oxide 2.21 Sodium carboxymethylcellulose 3. Of glycerin
30. Or gelatin 6. Of citric acid
4. Of Timor
0.1f total amount 100.0Of Test Example 1 Carrageenin foot floating control test To the three samples of poultices obtained in the above Examples and Comparative Example 1.2, an untreated (inflammatory agent injection only) control group, etc. were added. Tests were conducted on 6 groups according to the following method. Solid feed RC-4 (manufactured by Oriental Yeast Co., Ltd.) was used as the rearing feed, and both feed and water were allowed to be taken ad libitum.
Star male rat (weight 122-140?
, Japan Medical Science Animal Materials Research Institute) were used, with 10 animals per group.
予め動物の右足容積を測定した後、前日子製しておいた
1、0%カラゲニン生理食塩溶液(ピクニンA、逗子化
学、LotM−15)をO,1mM/footをウオー
キングパッド(Walking Pad)をとおして
定流皮下に注射し、直ちに被験薬剤を貼付または塗布し
パラフィンフィルム(American Can
Company)で被覆保護し、塩ビ製ホルダー内に拘
束した起炎剤注射3時間後に薬剤を取り除き、局所を清
浄し、足2.浮lll?容積を測定し、次式により浮牌
率を求めて検定を行った。After measuring the animal's right foot volume in advance, a 1.0% carrageenan saline solution (Pykunin A, Zushi Kagaku, LotM-15) prepared by Maeko was added to O, 1mM/foot on a walking pad. Immediately affix or apply the test drug to a paraffin film (American Can
After 3 hours of injection, the drug was removed, the local area was cleaned, and the feet were covered and protected in a PVC holder. Floating? The volume was measured, and the floating tile rate was calculated using the following formula and tested.
浮賎率(%)=(3時間後の定容積−起炎前足容積)/
起炎前足容積×100
なお、浮tit測定装置は、MK−500Digita
l Volume Meter(室町機械株)を用
い、データ処理は、MZ−80B(SHARP )によ
った。Floatation rate (%) = (Constant volume after 3 hours - Inflamed paw volume) /
Inflamed front paw volume x 100 The floating tit measuring device is MK-500Digita.
1 Volume Meter (Muromachi Kikai Co., Ltd.) was used, and data processing was performed using MZ-80B (SHARP).
試験結果は表1に示すとおりである。The test results are shown in Table 1.
この試験結果から明らかなように、本発明によって得ら
れたパップ剤は、カラゲニン浮蝕に対して顕著な抑制作
用があることが判る。As is clear from the test results, the poultice obtained according to the present invention has a remarkable inhibitory effect on carrageenan erosion.
表1
カラニゲン足課の浮ルおよび抑制率(%)ネ:p4o、
os
試験例2
毛細血管透過性亢進抑制試験
体重125〜145PのW i s t a r系雄性
ラットを1群10匹として用いた。Table 1 Float and suppression rate (%) of Calanigen foot section: p4o,
os Test Example 2 Test for Suppression of Capillary Hyperpermeability A group of 10 Wistar male rats weighing 125 to 145 P were used.
試験前日にラットの背部を電気バリカンおよび電気シェ
ーパを用いて広く除毛し、個別に収容した。On the day before the test, the backs of the rats were extensively shaved using electric clippers and an electric shaper and housed individually.
背部2ケ所(正中線の左右)に起炎物質(ビクニンA1
% カラニゲン生理食塩溶液)O,ImLを皮内注射し
て直ちに薬剤を貼付し、パラフィンフィルムで被覆保護
し、塩ビ製ホルダー内に拘束した。There is an inflammatory substance (Bikunin A1) in two places on the back (left and right of the midline).
% Calanigen physiological saline solution) O, ImL was injected intradermally, and the drug was immediately applied, covered and protected with paraffin film, and restrained in a PVC holder.
起炎側注射2時間30分後に1.0%Pantamin
Sk7 blue 生理食塩溶a(0,5mJ
l/100fB、W)を静注した。更に30分後に動物
を鼻血致死させ、背部皮膚を剥離し、色素漏出部を直径
15mの皮革用パンチで打ち抜き、0.3%NaユSO
φ水溶液、アセトン混液(3ニア)10m見を加えJu
高速ホモジナイザー(ヒスコトロン、500rpm/分
)でホモジネートして色素を抽出し、遠心分離(3,5
0Orpm、15m1nX2)t、た。遠心分離後、そ
の上清を分光光度計を用い、625nmで比色定量し、
検量線より漏出量を求めて検定を行った。1.0% Pantamin 2 hours and 30 minutes after injection on the inflamed side
Sk7 blue Physiological saline solution a (0.5mJ
l/100 fB, W) was injected intravenously. After another 30 minutes, the animals were sacrificed with nosebleeds, the back skin was peeled off, the pigment leakage area was punched out with a leather punch with a diameter of 15 m, and 0.3% NaSO was added.
Add φ aqueous solution and acetone mixture (3 near) for 10 m.
Homogenize with a high-speed homogenizer (Hiscotron, 500 rpm/min) to extract the dye, and centrifuge (3,5
0Orpm, 15m1nX2)t. After centrifugation, the supernatant was colorimetrically determined at 625 nm using a spectrophotometer.
The leakage amount was determined from the calibration curve and tested.
その試験結果は表2に示すとおりである。The test results are shown in Table 2.
この試験結果から明らかなようK、本発明によって得ら
れたパップ剤は、毛細血管透過性先進抑制に関してセイ
ヨウトチノミエキスおよびグアイアズレンよりも強いこ
とが判る。As is clear from the test results, the poultice obtained according to the present invention is stronger than horse chestnut flea extract and guaiazulene in terms of advanced inhibition of capillary permeability.
表2Table 2
Claims (4)
するパツプ剤。(1) A poultice characterized by containing aloe powder or aloe liquid.
記載のパツプ剤。(2) The poultice according to claim 1, wherein the base is an aqueous gel base.
項または第2項記載のパツプ剤。(3) Claim 1 in which the aloe liquid is aloe juice
The poultice according to item 1 or 2.
1項または第2項記載のパツプ剤。(4) The poultice according to claim 1 or 2, wherein the aloe liquid is an aloe extract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59249702A JPS61129117A (en) | 1984-11-28 | 1984-11-28 | Aloe-containing cataplasm |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP59249702A JPS61129117A (en) | 1984-11-28 | 1984-11-28 | Aloe-containing cataplasm |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS61129117A true JPS61129117A (en) | 1986-06-17 |
Family
ID=17196928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP59249702A Pending JPS61129117A (en) | 1984-11-28 | 1984-11-28 | Aloe-containing cataplasm |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS61129117A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0565530A1 (en) * | 1989-07-18 | 1993-10-20 | GERTNER, Sheldon | Method for treating arthritically inflamed body joints, particularly joints having gouty arthritis |
JPH08291057A (en) * | 1995-02-22 | 1996-11-05 | Yuutoku Yakuhin Kogyo Kk | Cataplasm |
-
1984
- 1984-11-28 JP JP59249702A patent/JPS61129117A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0565530A1 (en) * | 1989-07-18 | 1993-10-20 | GERTNER, Sheldon | Method for treating arthritically inflamed body joints, particularly joints having gouty arthritis |
EP0565530A4 (en) * | 1989-07-18 | 1994-04-06 | Sheldon Gertner | |
JPH08291057A (en) * | 1995-02-22 | 1996-11-05 | Yuutoku Yakuhin Kogyo Kk | Cataplasm |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023158064A (en) | Crude drug-containing pharmaceutical composition | |
NZ577604A (en) | Topical formulation and uses thereof | |
KR20070064411A (en) | Topical administration carrier composition and therapeutic formulations comprising same | |
JPS60104005A (en) | Skin beutifying cosmetic | |
KR20010041527A (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
JPS6360910A (en) | Skin drug for external use | |
JPS635378B2 (en) | ||
JPS61129117A (en) | Aloe-containing cataplasm | |
JPS59216812A (en) | Hair restoring agent | |
JPS6322510A (en) | External preparation for skin | |
JPH04124138A (en) | External preparation for skin | |
Surekha et al. | Emulgel-An Overview | |
JPS6360909A (en) | Skin drug for external use | |
US20190314325A1 (en) | Process and Method to Accelerate Cellular Regeneration, Healing and Wound Management | |
RU2283637C1 (en) | Plaster | |
JPH11180887A (en) | Anti-inflammatory analgesic patch | |
JPH0555485B2 (en) | ||
JP2010047535A (en) | Skin external preparation | |
JPS6322506A (en) | External preparation for skin | |
JPH03141213A (en) | Hair tonic | |
JPS584721A (en) | External agent for skin | |
JPS6256129B2 (en) | ||
JP3612731B2 (en) | Anti-inflammatory analgesic topical | |
JPS59181220A (en) | Skin stimulating agent | |
JPS6053150A (en) | Rubbery sticky bandage |